{"log_id": 5990291827766690784, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 1.4e-05, "average": 0.997678, "min": 0.98156}, "location": {"width": 627, "top": 146, "height": 48, "left": 149}, "words": "及新近出现的持续性的原因不明的疲乏)时,应立即停用阿戈美拉汀"}, {"probability": {"variance": 0.002055, "average": 0.99054, "min": 0.699426}, "location": {"width": 886, "top": 184, "height": 58, "left": 193}, "words": "有肝损伤危险因素的患者应慎用本品,如肥胖超重/非酒精性脂肪肝、糖尿病、过量饮酒、或正在"}, {"probability": {"variance": 4e-06, "average": 0.998714, "min": 0.992893}, "location": {"width": 278, "top": 256, "height": 36, "left": 149}, "words": "服用可能引起肝损害的药物等"}, {"probability": {"variance": 6.2e-05, "average": 0.996941, "min": 0.97329}, "location": {"width": 212, "top": 306, "height": 34, "left": 151}, "words": "儿童和青少年患者用药"}, {"probability": {"variance": 0.002075, "average": 0.991819, "min": 0.690168}, "location": {"width": 891, "top": 329, "height": 58, "left": 192}, "words": "阿戈美拉汀在18岁以下抑郁患者的疗效和安全性尚未建立,因此不推荐本品用于18岁以下抑郁症患"}, {"probability": {"variance": 8e-06, "average": 0.998775, "min": 0.986767}, "location": {"width": 933, "top": 377, "height": 59, "left": 152}, "words": "者的治疗。在儿童和青少年进行的临床试验中,与安慰剂组相比,接受其他抗抑郁药治疗者出现自杀相"}, {"probability": {"variance": 0.000225, "average": 0.993193, "min": 0.920847}, "location": {"width": 929, "top": 425, "height": 59, "left": 154}, "words": "关行为(自杀企图和自杀念头)、敌意(主要表现为攻击、对立行为和易怒)的发生率更高(参见【儿"}, {"probability": {"variance": 1e-06, "average": 0.99844, "min": 0.996456}, "location": {"width": 96, "top": 501, "height": 25, "left": 156}, "words": "童用药】)"}, {"probability": {"variance": 3e-06, "average": 0.998473, "min": 0.995447}, "location": {"width": 84, "top": 550, "height": 26, "left": 156}, "words": "老年用药"}, {"probability": {"variance": 0.000126, "average": 0.997038, "min": 0.924078}, "location": {"width": 889, "top": 568, "height": 57, "left": 196}, "words": "阿戈美拉汀在≥75岁患者中的疗效尚未建立。因此,该年龄组患者不应使用阿戈美拉汀(见【老年"}, {"probability": {"variance": 3.4e-05, "average": 0.996133, "min": 0.979408}, "location": {"width": 224, "top": 637, "height": 37, "left": 156}, "words": "用药】和【临床试验】)"}, {"probability": {"variance": 1e-06, "average": 0.999351, "min": 0.99748}, "location": {"width": 235, "top": 685, "height": 37, "left": 157}, "words": "伴有痴呆的老年患者用药"}, {"probability": {"variance": 3.5e-05, "average": 0.997645, "min": 0.965301}, "location": {"width": 878, "top": 710, "height": 57, "left": 201}, "words": "本品用于治疗伴有痴呆的老年抑郁症患者的疗效和安全性尚未得到证实,因此本品不应用于治疗"}, {"probability": {"variance": 1e-06, "average": 0.99941, "min": 0.997195}, "location": {"width": 255, "top": 780, "height": 35, "left": 158}, "words": "伴有痴呆的老年抑郁症患者"}, {"probability": {"variance": 0.011969, "average": 0.966655, "min": 0.57304}, "location": {"width": 249, "top": 828, "height": 36, "left": 159}, "words": "双相情感障碍/躁狂/轻躁狂:"}, {"probability": {"variance": 1.4e-05, "average": 0.998456, "min": 0.981041}, "location": {"width": 892, "top": 854, "height": 56, "left": 200}, "words": "阿戈美拉汀应慎用于有双相情感障碍、躁狂或轻躁狂发作史的患者。当患者出现了躁狂症状时,应"}, {"probability": {"variance": 0.000534, "average": 0.990588, "min": 0.90315}, "location": {"width": 345, "top": 920, "height": 39, "left": 167}, "words": "该停止使用本品(参见【不良反应】)"}, {"probability": {"variance": 0.000214, "average": 0.990533, "min": 0.957936}, "location": {"width": 132, "top": 975, "height": 34, "left": 161}, "words": "自杀/自杀念头"}, {"probability": {"variance": 1.7e-05, "average": 0.997518, "min": 0.977349}, "location": {"width": 891, "top": 998, "height": 56, "left": 203}, "words": "抑郁症本身会导致自杀念头、自伤和自杀行为(自杀相关事件)的风险增加。这种风险持续存在直"}, {"probability": {"variance": 1.1e-05, "average": 0.998606, "min": 0.98092}, "location": {"width": 932, "top": 1046, "height": 56, "left": 164}, "words": "至患者明显缓解。由于治疗最初几周或更长的时间内可能都没有改善,此时应对患者进行密切监测直至"}, {"probability": {"variance": 6e-06, "average": 0.998686, "min": 0.988269}, "location": {"width": 631, "top": 1102, "height": 49, "left": 165}, "words": "症状缓解。通常的临床经验是在患者康复期早期自杀风险会有所升高"}, {"probability": {"variance": 7e-06, "average": 0.998552, "min": 0.985081}, "location": {"width": 879, "top": 1142, "height": 54, "left": 207}, "words": "发生过自杀相关事件的患者或在治疗前即有严重自杀意念的患者是出现自杀念头或企图的高风险"}, {"probability": {"variance": 6e-06, "average": 0.998484, "min": 0.984778}, "location": {"width": 933, "top": 1188, "height": 58, "left": 166}, "words": "人群,治疗期间应密切监测。一项针对成人患者精神疾病的安慰剂对照的抗抑郁药临床研究的荟萃分析"}, {"probability": {"variance": 3e-06, "average": 0.999029, "min": 0.990219}, "location": {"width": 775, "top": 1241, "height": 54, "left": 168}, "words": "结果显示,与安慰剂相比,25岁以下患者在接受抗抑郁药治疗后自杀行为的风险增高"}, {"probability": {"variance": 0, "average": 0.998011, "min": 0.998011}, "location": {"width": 29, "top": 1263, "height": 30, "left": 967}, "words": "苏"}, {"probability": {"variance": 1e-06, "average": 0.999256, "min": 0.995932}, "location": {"width": 882, "top": 1286, "height": 56, "left": 210}, "words": "治疗过程中,特别是在治疗早期及改变剂量后应对患者进行严密观察,尤其是自杀风险高的患者"}, {"probability": {"variance": 7e-06, "average": 0.998189, "min": 0.98663}, "location": {"width": 932, "top": 1332, "height": 58, "left": 168}, "words": "应当告诫患者(以及患者的看护人),如果患者出现任何症状恶化、自杀行为或念头,以及行为的异常"}, {"probability": {"variance": 0, "average": 0.999405, "min": 0.997781}, "location": {"width": 342, "top": 1398, "height": 39, "left": 168}, "words": "改变,应当立即寻求医疗帮助和指导"}, {"probability": {"variance": 0.000162, "average": 0.995367, "min": 0.930157}, "location": {"width": 596, "top": 1436, "height": 50, "left": 172}, "words": "与CYP1A2抑制剂联合使用(参见【禁忌】和【药物相互作用】)"}, {"probability": {"variance": 0.00269, "average": 0.989576, "min": 0.649514}, "location": {"width": 891, "top": 1474, "height": 57, "left": 213}, "words": "本品与中度CYP1A2抑制剂(如:普萘洛尔、格帕沙星、依诺沙星)联用时会增加阿戈美拉汀的暴"}, {"probability": {"variance": 1e-06, "average": 0.999104, "min": 0.995964}, "location": {"width": 192, "top": 1547, "height": 32, "left": 171}, "words": "露量,处方时需谨慎"}], "language": 3}